ASCO 2022 Prostate Cancer - Results from #60

Viewing 61-80 of 82 articles

ASCO 2022: Reasons for Oncologist and Urologist Treatment Choice in Metastatic Castration-Sensitive Prostate Cancer: A Physician Survey Linked to Patient Chart Reviews in the United States

ASCO 2022: Open-Label Study of Androgen Receptor Inhibition With Darolutamide + ADT Versus ADT in Men With mHSPC Using an External Control Arm (ARASEC)

ASCO 2022: Efficacy and Safety of Relugolix in Men with Advanced Prostate Cancer Based on Baseline BMI: A Subgroup Analysis from the Randomized, Phase 3 HERO Study Versus Leuprolide

ASCO 2022: PSMA PET Tumor-to-Salivary Glands Ratio (PSG Score) To Predict Response to Lu-177 PSMA Radioligand Therapy: An International Multicenter Retrospective Study

ASCO 2022: Phase 3 VERACITY Clinical Study of Sabizabulin in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on an Androgen Receptor Targeting Agent

ASCO 2022: Alkaline Phosphatase Decline and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in the REASSURE Study

ASCO 2022: Piflufolastat F18-PET/CT in Patients With Prostate Cancer: An Analysis of OSPREY (Cohorts A and B) Standardized Uptake Value Results Stratified by PSA and Gleason Score

ASCO 2022: Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Castration-Sensitive Prostate Cancer: A Pooled Analysis of the STOMP and ORIOLE Trials

ASCO 2022: Making Sense of the Intensified mHSPC Landscape - Discussion

ASCO 2022: A Phase 3 Trial of SHR3680 Versus Bicalutamide in Combination With ADT in Patients With High-Volume mHSPC

ASCO 2022: Assessing Intermediate Clinical Endpoints As Potential Surrogates for Overall Survival in Men With mHSPC

ASCO 2022: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP

ASCO 2022: Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

ASCO 2022: Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

ASCO 2022: Updated Overall Survival Outcomes in ENZAMET (ANZUP 1304), an International, Cooperative Group Trial of Enzalutamide in mHSPC

ASCO 2022: [177Lu]Lu-PSMA-617 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial

ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)

ASCO 2022: [68Ga]Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for Clinical Outcomes to [177Lu]Lu-PSMA-617 in Patients With mCRPC: A VISION Substudy

ASCO 2022: Metastatic Castration-Resistant Prostate Cancer: The Future Is Now? - Discussion

ASCO 2022: Reimaging the Timing and Intensity of ADT in Biochemical Recurrence

1
2
3
4
5